The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 

A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.

Prednisolone monotherapy has been the standard systemic treatment in many patients with androgen- independent prostate cancer and should today be compared to treatment with Taxotere plus prednisolone. One hundred and thirty four patients were entered into a randomized phase II study [arm A: Taxotere plus prednisolone (30 mg/m2 weekly during 5 of 6 weeks + prednisolone 5 mg orally twice daily); arm B: prednisolone (5 mg orally twice daily)]. Biochemical response at 6 weeks was the primary outcome parameter, with progression-free and overall survival as secondary outcomes. Biochemical response at 6 weeks was recorded in 29 of 54 evaluable patients in arm A [54%; 95% confidence interval (CI) 40-67%] and 13 of 50 patients in arm B (26%; 95% CI 14-38%), with a similar difference in response rates at 12 weeks. Median progression-free survival was 11 months in arm A (95% CI 5.8-16.2)and 4 months in arm B (95% CI 2.4-5.6). Median overall survival was 27 months in arm A (95% CI 19.8-34.1) and 18 months in arm B (95% CI 15.2-20.8). Assessment of pain and quality of life showed superiority of arm A treatment, without unacceptable toxicity. Taxotere plus prednisolone is recommended as systemic standard treatment in androgen-independent prostate cancer.[1]

References

 
WikiGenes - Universities